Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9HCQ5
UPID:
GALT9_HUMAN
Alternative names:
Polypeptide GalNAc transferase 9; Protein-UDP acetylgalactosaminyltransferase 9; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 9
Alternative UPACC:
Q9HCQ5; Q52LR8; Q6NT54; Q8NFR1
Background:
Polypeptide N-acetylgalactosaminyltransferase 9, also known as Protein-UDP acetylgalactosaminyltransferase 9 or UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 9, plays a crucial role in the biosynthesis of O-linked oligosaccharides. It catalyzes the transfer of an N-acetyl-D-galactosamine residue to serine or threonine residues on protein receptors, a pivotal step in the post-translational modification of proteins.
Therapeutic significance:
Understanding the role of Polypeptide N-acetylgalactosaminyltransferase 9 could open doors to potential therapeutic strategies. Its involvement in the initial stages of oligosaccharide biosynthesis makes it a compelling target for the development of novel treatments.